瑞科生物-B(02179)新佐剂重组带状疱疹疫苗REC610 完成III期临床研究入组

智通财经
02 Jan

智通财经APP讯,瑞科生物-B(02179)公布,公司自主研发的新佐剂重组带状疱疹疫苗 REC610 III期临床研究已顺利完成全部受试者的入组。

该项临床研究采用随机、双盲、安慰剂对照设计,旨在评估REC610疫苗对40岁及以上健康受试者的保护效力、安全性及免疫原性,已在云南省、河南省和山西省共计18个研究中心招募24,640名受试者。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10